Howard S Kim1, Danielle M McCarthy2, D Mark Courtney3, Patrick M Lank3, Bruce L Lambert4. 1. Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Center for Education in Health Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. Electronic address: howard.kim@northwestern.edu. 2. Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States; Center for Education in Health Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. 3. Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. 4. Department of Communication Studies, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.
Abstract
BACKGROUND: Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression, and the rate of death due to benzodiazepine-opioid overdose is increasing. Little is known about the prevalence and characteristics of benzodiazepine-opioid co-prescribing from the ED setting. METHODS: Secondary analysis of data from the National Hospital Ambulatory Medical Care Survey, using sample weights to generate population estimates. The primary objective was to describe the annual prevalence of benzodiazepine-opioid co-prescribing from 2006 to 2012, using 95% confidence intervals (95% CI) to compare adjacent years. The secondary objective was to compare characteristics of ED encounters receiving a benzodiazepine-opioid co-prescription versus those receiving an opioid prescription alone, using a multivariable logistic regression. RESULTS: The prevalence of benzodiazepine-opioid co-prescribing did not significantly change from 2006 to 2012. During this period, 2.7% (95% CI: 2.5-2.8%) of ED encounters prescribed an opioid were also prescribed a benzodiazepine. Relative to encounters receiving an opioid prescription alone, encounters receiving a co-prescription were more likely to represent a follow-up rather than initial visit (Odds Ratio [OR] 1.52), receive more medications (OR 1.41) and fewer procedures (OR 0.48) while in the ED, and more likely to have a diagnosis related to mental disorder (OR 20.60) or musculoskeletal problem (OR 3.71). CONCLUSIONS: From 2006 to 2012, almost 3% of all ED encounters receiving an opioid prescription also received a benzodiazepine co-prescription. The odds of benzodiazepine-opioid co-prescribing were significantly higher in ED encounters representing a follow-up visit and in diagnoses relating to a mental disorder or musculoskeletal problem.
BACKGROUND:Benzodiazepine-opioid combination therapy is potentially harmful due to the risk of synergistic respiratory depression, and the rate of death due to benzodiazepine-opioid overdose is increasing. Little is known about the prevalence and characteristics of benzodiazepine-opioid co-prescribing from the ED setting. METHODS: Secondary analysis of data from the National Hospital Ambulatory Medical Care Survey, using sample weights to generate population estimates. The primary objective was to describe the annual prevalence of benzodiazepine-opioid co-prescribing from 2006 to 2012, using 95% confidence intervals (95% CI) to compare adjacent years. The secondary objective was to compare characteristics of ED encounters receiving a benzodiazepine-opioid co-prescription versus those receiving an opioid prescription alone, using a multivariable logistic regression. RESULTS: The prevalence of benzodiazepine-opioid co-prescribing did not significantly change from 2006 to 2012. During this period, 2.7% (95% CI: 2.5-2.8%) of ED encounters prescribed an opioid were also prescribed a benzodiazepine. Relative to encounters receiving an opioid prescription alone, encounters receiving a co-prescription were more likely to represent a follow-up rather than initial visit (Odds Ratio [OR] 1.52), receive more medications (OR 1.41) and fewer procedures (OR 0.48) while in the ED, and more likely to have a diagnosis related to mental disorder (OR 20.60) or musculoskeletal problem (OR 3.71). CONCLUSIONS: From 2006 to 2012, almost 3% of all ED encounters receiving an opioid prescription also received a benzodiazepine co-prescription. The odds of benzodiazepine-opioid co-prescribing were significantly higher in ED encounters representing a follow-up visit and in diagnoses relating to a mental disorder or musculoskeletal problem.
Authors: Howard S Kim; Danielle M McCarthy; Jason A Hoppe; D Mark Courtney; Bruce L Lambert Journal: Acad Emerg Med Date: 2017-09-19 Impact factor: 3.451
Authors: Tracy E Madsen; Samuel McLean; Wanting Zhai; Sarah Linnstaedt; Michael C Kurz; Robert Swor; Phyllis Hendry; David Peak; Christopher Lewandowski; Claire Pearson; Brian O'Neil; Elizabeth Datner; David Lee; Francesca Beaudoin Journal: Clin Ther Date: 2018-01-20 Impact factor: 3.393
Authors: Howard S Kim; Jody D Ciolino; Nicola Lancki; Kyle J Strickland; Daniel Pinto; Christine Stankiewicz; D Mark Courtney; Bruce L Lambert; Danielle M McCarthy Journal: Phys Ther Date: 2021-03-03
Authors: Ljiljana Trtica Majnarić; Thomas Wittlinger; Dunja Stolnik; František Babič; Zvonimir Bosnić; Stjepan Rudan Journal: Int J Environ Res Public Health Date: 2020-06-05 Impact factor: 3.390